Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 101

Similar articles for PubMed (Select 11850144)

1.

Amphetamine-induced dopamine release and post-synaptic specific binding in patients with mild tardive dyskinesia.

Adler CM, Malhotra AK, Elman I, Pickar D, Breier A.

Neuropsychopharmacology. 2002 Mar;26(3):295-300.

2.

Binding characteristics and sensitivity to endogenous dopamine of [11C]-(+)-PHNO, a new agonist radiotracer for imaging the high-affinity state of D2 receptors in vivo using positron emission tomography.

Ginovart N, Galineau L, Willeit M, Mizrahi R, Bloomfield PM, Seeman P, Houle S, Kapur S, Wilson AA.

J Neurochem. 2006 May;97(4):1089-103. Epub 2006 Apr 5.

PMID:
16606355
3.

Dopaminergic activity in Tourette syndrome and obsessive-compulsive disorder.

Denys D, de Vries F, Cath D, Figee M, Vulink N, Veltman DJ, van der Doef TF, Boellaard R, Westenberg H, van Balkom A, Lammertsma AA, van Berckel BN.

Eur Neuropsychopharmacol. 2013 Nov;23(11):1423-31. doi: 10.1016/j.euroneuro.2013.05.012. Epub 2013 Jul 19.

4.

Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: evidence from a novel positron emission tomography method.

Breier A, Su TP, Saunders R, Carson RE, Kolachana BS, de Bartolomeis A, Weinberger DR, Weisenfeld N, Malhotra AK, Eckelman WC, Pickar D.

Proc Natl Acad Sci U S A. 1997 Mar 18;94(6):2569-74.

5.

Effects of amphetamine and evoked dopamine release on [11C]raclopride binding in anesthetized cats.

Ginovart N, Hassoun W, Le Cavorsin M, Veyre L, Le Bars D, Leviel V.

Neuropsychopharmacology. 2002 Jul;27(1):72-84.

6.

Effect of amphetamine-induced dopamine release on radiotracer binding to D1 and D2 receptors in rat brain striatal slices.

Gifford AN, Park MH, Kash TL, Herman LM, Park EH, Gatley SJ, Volkow ND.

Naunyn Schmiedebergs Arch Pharmacol. 2000 Nov;362(4-5):413-8.

PMID:
11111836
7.

GBR12909 attenuates amphetamine-induced striatal dopamine release as measured by [(11)C]raclopride continuous infusion PET scans.

Villemagne VL, Wong DF, Yokoi F, Stephane M, Rice KC, Matecka D, Clough DJ, Dannals RF, Rothman RB.

Synapse. 1999 Sep 15;33(4):268-73.

PMID:
10421707
8.

Modulation of striatal dopamine release by 5-HT2A and 5-HT2C receptor antagonists: [11C]raclopride PET studies in the rat.

Egerton A, Ahmad R, Hirani E, Grasby PM.

Psychopharmacology (Berl). 2008 Nov;200(4):487-96. doi: 10.1007/s00213-008-1226-4. Epub 2008 Jul 3.

PMID:
18597077
9.

Imaging human mesolimbic dopamine transmission with positron emission tomography. Part II: amphetamine-induced dopamine release in the functional subdivisions of the striatum.

Martinez D, Slifstein M, Broft A, Mawlawi O, Hwang DR, Huang Y, Cooper T, Kegeles L, Zarahn E, Abi-Dargham A, Haber SN, Laruelle M.

J Cereb Blood Flow Metab. 2003 Mar;23(3):285-300.

PMID:
12621304
10.

Amphetamine-induced displacement of [18F] fallypride in striatum and extrastriatal regions in humans.

Riccardi P, Li R, Ansari MS, Zald D, Park S, Dawant B, Anderson S, Doop M, Woodward N, Schoenberg E, Schmidt D, Baldwin R, Kessler R.

Neuropsychopharmacology. 2006 May;31(5):1016-26.

11.

MDMA-evoked changes in [11C]raclopride and [11C]NMSP binding in living pig brain.

Rosa-Neto P, Gjedde A, Olsen AK, Jensen SB, Munk OL, Watanabe H, Cumming P.

Synapse. 2004 Sep 15;53(4):222-33.

PMID:
15266554
12.

Levodopa-induced changes in synaptic dopamine in patients with Parkinson's disease as measured by [11C]raclopride displacement and PET.

Tedroff J, Pedersen M, Aquilonius SM, Hartvig P, Jacobsson G, Långström B.

Neurology. 1996 May;46(5):1430-6.

PMID:
8628494
13.

A comparative evaluation of the dopamine D(2/3) agonist radiotracer [11C](-)-N-propyl-norapomorphine and antagonist [11C]raclopride to measure amphetamine-induced dopamine release in the human striatum.

Narendran R, Mason NS, Laymon CM, Lopresti BJ, Velasquez ND, May MA, Kendro S, Martinez D, Mathis CA, Frankle WG.

J Pharmacol Exp Ther. 2010 May;333(2):533-9. doi: 10.1124/jpet.109.163501. Epub 2010 Jan 26.

14.

Dopaminergic activity in depressed smokers: a positron emission tomography study.

Busto UE, Redden L, Mayberg H, Kapur S, Houle S, Zawertailo LA.

Synapse. 2009 Aug;63(8):681-9. doi: 10.1002/syn.20646.

15.

PET measures of amphetamine-induced dopamine release in ventral versus dorsal striatum.

Drevets WC, Price JC, Kupfer DJ, Kinahan PE, Lopresti B, Holt D, Mathis C.

Neuropsychopharmacology. 1999 Dec;21(6):694-709.

16.

In vivo vulnerability to competition by endogenous dopamine: comparison of the D2 receptor agonist radiotracer (-)-N-[11C]propyl-norapomorphine ([11C]NPA) with the D2 receptor antagonist radiotracer [11C]-raclopride.

Narendran R, Hwang DR, Slifstein M, Talbot PS, Erritzoe D, Huang Y, Cooper TB, Martinez D, Kegeles LS, Abi-Dargham A, Laruelle M.

Synapse. 2004 Jun 1;52(3):188-208.

PMID:
15065219
17.

Chronic interferon-α decreases dopamine 2 receptor binding and striatal dopamine release in association with anhedonia-like behavior in nonhuman primates.

Felger JC, Mun J, Kimmel HL, Nye JA, Drake DF, Hernandez CR, Freeman AA, Rye DB, Goodman MM, Howell LL, Miller AH.

Neuropsychopharmacology. 2013 Oct;38(11):2179-87. doi: 10.1038/npp.2013.115. Epub 2013 May 9.

18.

Effect of amphetamine on dopamine D2 receptor binding in nonhuman primate brain: a comparison of the agonist radioligand [11C]MNPA and antagonist [11C]raclopride.

Seneca N, Finnema SJ, Farde L, Gulyás B, Wikström HV, Halldin C, Innis RB.

Synapse. 2006 Apr;59(5):260-9.

PMID:
16416444
20.

Striatal binding of the PET ligand 11C-raclopride is altered by drugs that modify synaptic dopamine levels.

Dewey SL, Smith GS, Logan J, Brodie JD, Fowler JS, Wolf AP.

Synapse. 1993 Apr;13(4):350-6.

PMID:
8480281
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk